Demand for clinician education, peer-to-peer learning, and clinical collaboration continues to grow, yet many MedTech organizations still rely on emails, spreadsheets, and disconnected processes to manage training requests, faculty engagement, scheduling, logistics, and program tracking. As programs expand, these manual approaches can create operational bottlenecks, limited visibility, inconsistent learner experiences, and challenges in measuring impact. 

Join us for a discussion on the challenges of scaling peer-to-peer education and how MedTech organizations can use collaboration platforms to create a more connected, efficient, and measurable approach to education management. We'll explore common industry pain points, the limitations of manual processes, and the role a centralized collaboration platform can play in streamlining program coordination, improving visibility across stakeholders, supporting growth, and reducing operational complexity. 

AI is rapidly moving from a theoretical concept to an operational reality across medical device software, automated product development, and quality management systems. But as adoption grows, critical questions emerge: Who approves AI implementation? How are outputs validated? Who is accountable when an algorithm fails or drifts? Without clear AI governance, organizations risk hitting regulatory bottlenecks, delaying product releases, or exposing themselves to compliance failures. However, overly restrictive models can stifle innovation when agility matters most.

Join agilityIRL next month for an interactive, practical panel discussion on how leading MedTech organizations structure AI oversight. We will move beyond high-level definitions to examine real-world organizational models, compare centralized versus decentralized governance frameworks, and evaluate how to align AI risk controls with your existing Quality Management System (QMS).

Key Takeaways:

1. Evaluation Checklist: Learn specific criteria to determine which AI governance model fits your organization’s risk profile and operational maturity.

2. Case Study Insights: Explore how peer organizations structured early wins, avoided common oversight pitfalls, and handled escalation pathways.

3. Actionable QMS Integration: Leave with a clear map of where AI oversight intersects with existing design controls, risk files, and change management.

4. Immediate Next Steps: Get a set of diagnostic questions to audit current baseline AI usage across your engineering and quality teams today.

Despite heavy software investments, only 19% of medtech companies achieve universal adoption across field tools - leaving 68% of leaders facing a critical insight gap where sales data lacks depth and delivers zero actionable guidance.

The problem isn’t field effort; reps represent a company’s largest SG&A investment and richest data source. However, forcing them to fill out rigid picklists between procedure rooms creates heavy admin drag. Crucial qualitative insights vanish the second a rep leaves an account, forcing leadership to make multi-million-dollar decisions based on bare-minimum checkbox logs.

Join Jeff Gorski (Veeva MedTech) to explore how forward-thinking medtech leaders use Agentic AI to eliminate this friction. Learn how Conversational AI delivers pre-call guidance, how Agentic Call Reports™ enable instant voice debriefs, and how converting field notes into Commercial Evidence gives leaders real-time clarity across care providers - clearing adoption barriers, driving top-line growth, and getting treatments to patients faster.

Key Takeaways:

• Eliminate Admin Drag: How conversational prep and post-call voice debriefs save reps hours while maintaining automated compliance.

• Close the Insight Gap: Why legacy tools fail in clinical workflows and how usability drag threatens revenue targets.

• Generate Commercial Evidence: How AI turns unstructured field notes into clean market signals - revealing 65% more actionable account barriers.
• Drive Rep-Centric Execution: Practical steps to share real-time data back to field reps to build adoption and accelerate product delivery.

From AI-powered diagnostics to gene-editing cures, medical innovation is accelerating faster than most investors realize, and it's reshaping how long, and how well, we live. In this session, Sean McDermott, Founder and President of Summit Investment Advisors and guest speaker Dr. Ovid Amadi, portfolio manager at ARK Investment Management, will discuss the AI-driven trends transforming genomics, drug development, and longevity science, and how these shifts are opening new opportunities in the market.

You'll leave with:

- An inside look at the science and economics behind AI-powered medical breakthroughs

- A view on where healthcare and MedTech stand today relative to the broader market

- Practical considerations for aligning your investment strategy with these long-term trends